Skip to main content

Table 1 Patient characteristics (n=501)

From: Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT

Variable Male Female P
Median age, years
Range
 < 45 177(46.6%) 75(62.0%) 0.003
 ≥45 203(53.4%) 46(38.0%)  
Marital status
 Married 17(4.5%) 6(5.0%) 0.833
 Single 363(95.3%) 115(95.0%)  
Education years
 No formal education 6(1.6%) 7(5.8%) 0.065
 Primary level 49(12.9%) 20(16.5%)  
 Secondary level 99(26.1%) 24(19.8%)  
 High school 112(29.5%) 37(30.6%)  
 University 114(30.0%) 33(27.3%)  
Smoking history
 Ever 159(41.8%) 116(4.1%) <0.0001
 Never 221(58.2%) 5(95.9%)  
Alcohol history <0.0001
 Ever 53(13.9%) 0(0)  
 Never 327(86.1%) 121(100.0%)  
ECOG score 0.174
 0 378(99.7%) 118(99.2%)  
 1 0(0) 1(0.8)  
 2 1(0.3%) 0(0)  
WHO type 0.862
 1 2(0.5%) 1(0.8%)  
 2 2(0.5%) 1(0.8%)  
 3 375(98.9%) 117(98.3%)  
T stage 0.521
 1 19(5.0%) 3(2.5%)  
 2 67(17.6%) 18(14.9%)  
 3 202(53.2%) 71(58.7%)  
 4 92(24.2%) 29(24.0%)  
N stage 0.641
 0 50(13.2%) 11(9.1%)  
 1 144(37.9%) 51(42.1%)  
 2 146(38.4%) 45(37.2%)  
 3 40(10.5%) 14(11.6%)  
AJCC stage 0.322
 1 7(1.8%) 2(1.7%)  
 2 44(11.6%) 7(5.8%)  
 3 207(54.5%) 72(59.5%)  
 4 122(32.1%) 40(33.1%)  
Treatment modality
 RT 27(7.1%) 9(7.4%)  
 IC + CCRT 194(51.1%) 60(49.6%)  
 CCRT 159(41.8%) 52(43.0%)  
Median RT dose, Gy
VCA IgA 0.188
  < 1:80 151(39.7%) 40(33.1%)  
  ≥ 1:80 229(60.3%) 81(66.9%)  
EA IgA 0.138
  < 1:10 199(52.4%) 54(44.6%)  
  ≥ 1:10 181(47.6%) 67(55.4%)  
Pre-EBV DNA 0.526
  ≤ 4000 201 (52.9%) 60(49.6%)  
  > 4000 179 (47.1%) 61(50.4%)  
Post-EBV DNA 0.780
 negative 136(35.8%) 45(37.2%)  
 positive 244(64.2%) 76(62.8%)  
Family history of NPC 0.252
 yes 18(4.7%) 9(7.4%)  
 no 362 (95.3%) 112(92.6%)  
  1. Abbrevations. No Number, ECOG Eastern Cooperative Oncology Group, WHO World Health Organization, AJCC American Joint Committee on Cancer, RT Radiotherapy, IC Induction chemotherapy, CCRT Concurrent chemoradiotherapy, EBV DNA Epstein-Barr virus deoxyribonucleic acid, NPC Nasopharyngeal carcinoma
\